NASDAQ:ALT

Altimmune News Headlines

$11.81
+0.03 (+0.25 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.35
Now: $11.81▼
$12.16
50-Day Range
$11.78
MA: $14.29▼
$17.73
52-Week Range
$2.88
Now: $11.81▼
$35.10
Volume671,181 shs
Average Volume1.55 million shs
Market Capitalization$438.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51

Headlines

Altimmune (NASDAQ ALT) News Headlines Today

SourceHeadline
ALT.O - Altimmune Inc Profile | ReutersALT.O - Altimmune Inc Profile | Reuters
reuters.com - April 19 at 2:15 AM
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Buy" by AnalystsAltimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - April 18 at 2:44 AM
$2.19 Million in Sales Expected for Altimmune, Inc. (NASDAQ:ALT) This Quarter$2.19 Million in Sales Expected for Altimmune, Inc. (NASDAQ:ALT) This Quarter
americanbankingnews.com - April 17 at 3:42 AM
Short Interest in Altimmune, Inc. (NASDAQ:ALT) Grows By 82.5%Short Interest in Altimmune, Inc. (NASDAQ:ALT) Grows By 82.5%
americanbankingnews.com - April 17 at 1:00 AM
Altimmune, Inc. (NASDAQ:ALT) Expected to Announce Earnings of -$0.39 Per ShareAltimmune, Inc. (NASDAQ:ALT) Expected to Announce Earnings of -$0.39 Per Share
americanbankingnews.com - April 15 at 6:08 AM
Could AstraZenecas Nasal COVID Vaccine Development Zap Altimmunes Prospects? - Motley FoolCould AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects? - Motley Fool
fool.com - April 10 at 6:13 AM
Estimating The Intrinsic Value Of Altimmune, Inc. (NASDAQ:ALT) - NasdaqEstimating The Intrinsic Value Of Altimmune, Inc. (NASDAQ:ALT) - Nasdaq
nasdaq.com - April 7 at 5:15 AM
A Look At The Fair Value Of Altimmune, Inc. (NASDAQ:ALT) - Yahoo FinanceA Look At The Fair Value Of Altimmune, Inc. (NASDAQ:ALT) - Yahoo Finance
finance.yahoo.com - April 3 at 9:21 AM
A Look At The Fair Value Of Altimmune, Inc. (NASDAQ:ALT)A Look At The Fair Value Of Altimmune, Inc. (NASDAQ:ALT)
finance.yahoo.com - April 3 at 9:21 AM
Altimmune highlights safety of anthrax vaccine candidate with early-stage results - Seeking AlphaAltimmune highlights safety of anthrax vaccine candidate with early-stage results - Seeking Alpha
seekingalpha.com - April 1 at 5:58 PM
Altimmune (ALT) Reports Data from its Phase 1b Clinical Trial of NasoShield - StreetInsider.comAltimmune (ALT) Reports Data from its Phase 1b Clinical Trial of NasoShield - StreetInsider.com
streetinsider.com - April 1 at 2:36 PM
Altimmunes Anthrax Vaccine Candidate Shows Early Safety, Immunogenicity In Healthy Volunteers - Yahoo FinanceAltimmune's Anthrax Vaccine Candidate Shows Early Safety, Immunogenicity In Healthy Volunteers - Yahoo Finance
finance.yahoo.com - April 1 at 2:36 PM
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™ - Yahoo FinanceAltimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™ - Yahoo Finance
finance.yahoo.com - April 1 at 2:36 PM
Altimmunes Anthrax Vaccine Candidate Shows Early Safety, Immunogenicity In Healthy Volunteers - BenzingaAltimmune's Anthrax Vaccine Candidate Shows Early Safety, Immunogenicity In Healthy Volunteers - Benzinga
benzinga.com - April 1 at 9:35 AM
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™ - GlobeNewswireAltimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™ - GlobeNewswire
globenewswire.com - April 1 at 9:35 AM
BRIEF-Altimmune Reports Data From Its Phase 1B Clinical Trial Of NasoshieldBRIEF-Altimmune Reports Data From Its Phase 1B Clinical Trial Of Nasoshield
msn.com - April 1 at 7:56 AM
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
finance.yahoo.com - April 1 at 7:55 AM
Altimmune Stock Is Believed To Be Significantly Overvalued - Yahoo FinanceAltimmune Stock Is Believed To Be Significantly Overvalued - Yahoo Finance
finance.yahoo.com - March 27 at 4:25 AM
AstraZeneca’s COVID-19 nasal spray sparks interest in Altimmune - Seeking AlphaAstraZeneca’s COVID-19 nasal spray sparks interest in Altimmune - Seeking Alpha
seekingalpha.com - March 26 at 6:23 PM
Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID(TM) Vaccine CandidateAltimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID(TM) Vaccine Candidate
marketwatch.com - March 23 at 8:01 PM
Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate - GlobeNewswireAltimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate - GlobeNewswire
globenewswire.com - March 22 at 7:36 AM
Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine CandidateAltimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate
finance.yahoo.com - March 22 at 7:36 AM
Is Altimmune a Buy?Is Altimmune a Buy?
nasdaq.com - March 20 at 5:53 PM
Is Altimmune a Buy? - Motley FoolIs Altimmune a Buy? - Motley Fool
fool.com - March 20 at 7:52 AM
AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection - Yahoo FinanceAdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection - Yahoo Finance
finance.yahoo.com - March 17 at 10:50 PM
Altimmunes Shares Are Trading Higher On Intranasal COVID-19 Vaccine Candidates Promising Action In Animal Studies - BenzingaAltimmune's Shares Are Trading Higher On Intranasal COVID-19 Vaccine Candidate's Promising Action In Animal Studies - Benzinga
benzinga.com - March 16 at 3:16 PM
Altimmunes Shares Are Trading Higher On Intranasal COVID-19 Vaccine Candidates Promising Action In Animal Studies - Yahoo FinanceAltimmune's Shares Are Trading Higher On Intranasal COVID-19 Vaccine Candidate's Promising Action In Animal Studies - Yahoo Finance
finance.yahoo.com - March 15 at 11:50 PM
Altimmune shares rise on encouraging COVID-19 vaccine data in mouse model - Seeking AlphaAltimmune shares rise on encouraging COVID-19 vaccine data in mouse model - Seeking Alpha
seekingalpha.com - March 15 at 1:28 PM
AdCOVID™, Altimmunes Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection - GlobeNewswireAdCOVID™, Altimmune's Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection - GlobeNewswire
globenewswire.com - March 15 at 9:22 AM
Altimmunes Shares Are Trading Higher On Intranasal COVID-19 Vaccine Candidates Promising Action In Animal StudiesAltimmune's Shares Are Trading Higher On Intranasal COVID-19 Vaccine Candidate's Promising Action In Animal Studies
markets.businessinsider.com - March 15 at 8:26 AM
AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 InfectionAdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
finance.yahoo.com - March 15 at 8:26 AM
Altimmune Extends Lonza Partnership To Support Production Of AdCOVID - Yahoo FinanceAltimmune Extends Lonza Partnership To Support Production Of AdCOVID - Yahoo Finance
finance.yahoo.com - March 14 at 6:34 PM
Altimmune Extends Lonza Partnership To Support Production Of AdCOVIDAltimmune Extends Lonza Partnership To Support Production Of AdCOVID
finance.yahoo.com - March 14 at 7:58 AM
Lonza to commission Houston suite to supply Altimmunes COVID-19 vaccine candidate - ReutersLonza to commission Houston suite to supply Altimmune's COVID-19 vaccine candidate - Reuters
reuters.com - March 13 at 10:51 AM
Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza - GlobeNewswireAltimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza - GlobeNewswire
globenewswire.com - March 13 at 10:51 AM
Altimmune (ALT) Expands AdCOVID Manufacturing Collaboration with Lonza - StreetInsider.comAltimmune (ALT) Expands AdCOVID Manufacturing Collaboration with Lonza - StreetInsider.com
streetinsider.com - March 13 at 2:53 AM
UPDATE 1-Lonza to commission Houston suite to supply Altimmunes COVID-19 vaccine candidate - Yahoo FinanceUPDATE 1-Lonza to commission Houston suite to supply Altimmune's COVID-19 vaccine candidate - Yahoo Finance
finance.yahoo.com - March 12 at 9:53 PM
Altimmune expands AdCOVID manufacturing pact with Lonza - Seeking AlphaAltimmune expands AdCOVID manufacturing pact with Lonza - Seeking Alpha
seekingalpha.com - March 12 at 9:13 PM
Altimmune Shares Are Trading Higher On Expanded Manufacturing Pact With LonzaAltimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza
finance.yahoo.com - March 12 at 3:39 PM
Lonza to commission Houston suite to supply Altimmunes COVID-19 vaccine candidateLonza to commission Houston suite to supply Altimmune's COVID-19 vaccine candidate
msn.com - March 12 at 3:39 PM
Altimmune expands manufacturing deal for experimental Covid-19 vaccineAltimmune expands manufacturing deal for experimental Covid-19 vaccine
bizjournals.com - March 12 at 3:39 PM
Why ContraFect, Evoke, Altimmune, Novavax Are Moving FridayWhy ContraFect, Evoke, Altimmune, Novavax Are Moving Friday
markets.businessinsider.com - March 12 at 3:39 PM
Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday - BenzingaWhy ContraFect, Evoke, Altimmune, Novavax Are Moving Friday - Benzinga
benzinga.com - March 12 at 2:42 PM
Altimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza - BenzingaAltimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza - Benzinga
benzinga.com - March 12 at 9:15 AM
Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza - Yahoo FinanceAltimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza - Yahoo Finance
finance.yahoo.com - March 12 at 9:15 AM
Altimmune Expands AdCOVID™ Manufacturing Collaboration with LonzaAltimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
finance.yahoo.com - March 12 at 9:15 AM
Altimmune Joins Rank Of Stocks With RS Ratings Over 90Altimmune Joins Rank Of Stocks With RS Ratings Over 90
finance.yahoo.com - March 10 at 12:39 PM
Altimmune to Present at Upcoming Conferences - Yahoo FinanceAltimmune to Present at Upcoming Conferences - Yahoo Finance
finance.yahoo.com - March 9 at 6:09 PM
Altimmune Joins Rank Of Stocks With RS Ratings Over 90 - Investors Business DailyAltimmune Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily
investors.com - March 9 at 1:09 PM
Altimmune to Present at Upcoming Conferences Nasdaq:ALT - GlobeNewswireAltimmune to Present at Upcoming Conferences Nasdaq:ALT - GlobeNewswire
globenewswire.com - March 8 at 6:13 PM
This page was last updated on 4/21/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.